Multidrug Resistance in Cancer Cells: Focus on a Possible Strategy Plan to Address Colon Carcinoma Cells
Open accessThe DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.
Abstract
Even though various treatment methods are available for cancer, the death curve is not reducing. The diagnosis of cancer at the fourth stage and drug resistance are the leading reasons for treatment failure and lower survival rates. In this review article, we summarize the possible pitfalls during cancer treatment in general, which mainly include multidrug resistance, and propose a hypothesis for colorectal cancer specifically. We also evaluate multidrug resistance in cancer in general and colorectal cancer in particular and hypothesize a concept based on combination therapy with 5-fluorouracil, curcumin, and lipids for the possible management of colorectal cancer. In addition, a hypothetical approach, combining a synthetic agent and a natural chemotherapeutic agent, to treating colorectal cancer is also discussed. This hypothesis could improve the management of colorectal cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Overexpression of ABC transporters is thought to be the main cause of MDR in cancer cells [45].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, defective apoptotic pathways can contribute to MDR [45].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [45]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Multiple strategies with the synergistic approach for addressing colorectal cancer
Karthika, C., Hari, B., Rahman, M. H., Akter, R., Najda, A., Albadrani, G. M., Sayed, A. A., Akhtar, M. F., & Abdel‐Daim, M. M. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111704 · Cited by 43 · cited 1×
“When colorectal cancer is detected in its early stages, surgery is the most commonly used treatment [65].”
BackgroundSelf-citationRetractedEngineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933 · cited 1×
“Because lipid-based drug delivery travels through the lymphatic system, including lipids in this combination [73] can help with cancer cell targeting and even treatment during the metastatic stage [74].”
BackgroundThe blood–brain barrier and blood–tumour barrier in brain tumours and metastases
Arvanitis, C. D., Ferraro, G. B., & Jain, R. K. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0205-x · Cited by 1,792 · cited 2×
“the body where the drug cannot be accessed or the tumor comprises compromised vasculature [43].”
BackgroundMechanisms of Multidrug Resistance in Cancer Chemotherapy
Bukowski, K., Kciuk, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093233 · Cited by 1,757 · cited 1×
“P-gp is the main reason for MDR in cancer cells [76].”
BackgroundTargeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials
Cheng, Y., He, C., Wang, M., Ma, X., Mo, F., Yang, S., Han, J., & Wei, X. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0095-0 · Cited by 1,097 · cited 1×
“Even though these are the major differences between MRP and MDR1 P-gp in the drugs that they transport or interact with, the drugs on which these two proteins act are varied, and the inhibitors that modify their activities are also different [52].”
BackgroundSawicki, T., Ruszkowska, M., Danielewicz, A., Niedźwiedzka, E., Arłukowicz, T., & Przybyłowicz, K. E. (2021) · Cancers · doi:10.3390/cancers13092025 · Cited by 921 · cited 1×
“Although the precise causes of colorectal cancer are indefinite, experts believe that diet plays an important role [6].”
BackgroundTherapeutic Potential of Quercetin: New Insights and Perspectives for Human Health
Salehi, B., Machin, L., Monzote, L., Sharifi-Rad, J., Ezzat, S. M., Salem, M. A., Merghany, R. M., El Mahdy, N. M., Kılıç, C. S., Sytar, O., et al. (2020) · ACS Omega · doi:10.1021/acsomega.0c01818 · Cited by 707 · cited 1×
“Because flavonoids have a synergistic effect on cancer cells [94], our anticipated formulation will reduce the drug’s dosing frequency even further [95].”
BackgroundGlobal cancer incidence in older adults, 2012 and 2035: A population‐based study
Pilleron, S., Sarfati, D., Janssen‐Heijnen, M., Vignat, J., Ferlay, J., Bray, F., & Soerjomataram, I. (2019) · International Journal of Cancer · doi:10.1002/ijc.31664 · Cited by 670 · cited 1×
“This figure is predicted to rise to 24 million by 2035 [5].”
BackgroundZebrafish disease models in drug discovery: from preclinical modelling to clinical trials
Patton, E. E., Zon, L. I., & Langenau, D. M. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00210-8 · Cited by 567 · cited 1×
“This mechanism has been studied in considerable detail and has enabled the development of an understanding of how drugs are handled in the body, based on how cancer cells handle these drugs [18].”
BackgroundThe multi-factorial nature of clinical multidrug resistance in cancer
Assaraf, Y. G., Brozovic, A., Gonçalves, A. C., Jurkovicova, D., Linē, A., Machuqueiro, M., Saponara, S., Sarmento-Ribeiro, A. B., Xavier, C. P. R., & Vasconcelos, M. H. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.100645 · Cited by 528 · cited 1×
“1980s: Multidrug resistance was shown, in most cases, to result from decreased intercellular drug accumulation, apparently as a result of alterations in the plasma membrane [28].”
BackgroundMcMahon, C. M., Ferng, T., Canaani, J., Wang, E. S., Morrissette, J. J. D., Eastburn, D. J., Pellegrino, M., Durruthy-Durruthy, R., Watt, C. D., Asthana, S., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1453 · Cited by 446 · cited 1×
“There may be resistant insensitive cells in the initial group, but during treatment, an additional mechanism of resistance can become evolved, which may become fixed during treatment, leading to mixed resistance [13].”
BackgroundCarriers Break Barriers in Drug Delivery: Endocytosis and Endosomal Escape of Gene Delivery Vectors
Degors, I. M. S., Wang, C., Rehman, Z. U., & Zuhorn, I. S. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00177 · Cited by 424 · cited 1×
“This model can be used to study drug release due to bond dissociation [92].”
MethodRegulation of cancer cell metabolism: Oncogenic MYC in the driver’s seat
Dong, Y., Tu, R., Liu, H., & Qing, G. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00235-2 · Cited by 405
A guide to plasma membrane solute carrier proteins
Pizzagalli, M. D., Bensimon, A., & Superti‐Furga, G. (2021) · The FEBS Journal · doi:10.1111/febs.15531 · Cited by 379 · cited 1×
“The first, and most obvious, is when drugs simply do not enter cells; nearly 400 different solute carriers are responsible for the movement of normal nutrients [22].”
BackgroundTargeting Cancer Cell Dormancy
Recasens, A., & Munoz, L. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.12.004 · Cited by 356 · cited 1×
“Most cancer cells have become drug-resistant, necessitating the development of a new strategy to overcome this resistance and ensure the success of the therapy [69].”
BackgroundRoss, D. D., Yang, W., Abruzzo, L. V., Dalton, W. S., Schneider, E., Lage, H., Dietel, M., Greenberger, L., Cole, S. P. C., & Doyle, L. A. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.5.429 · Cited by 350
Therapeutic targeting of 3′,5′-cyclic nucleotide phosphodiesterases: inhibition and beyond
Baillie, G. S., Tejeda, G. S., & Kelly, M. P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0033-4 · Cited by 339 · cited 1×
“Even the compartmentalization of drugs within subcellular compartments prevents them from reaching their targets [25].”
BackgroundDeep learning-based survival prediction of oral cancer patients
Kim, D. W., Lee, S., Kwon, S., Nam, W., Cha, I.-H., & Kim, H. J. (2019) · Scientific Reports · doi:10.1038/s41598-019-43372-7 · Cited by 320 · cited 1×
“Although various cancer treatment methods are available, the death curve is not reducing [1].”
BackgroundImprovement of conventional anti-cancer drugs as new tools against multidrug resistant tumors
Dallavalle, S., Dobričić, V., Lazzarato, L., Gazzano, E., Machuqueiro, M., Pajeva, I., Tsakovska, I., Zidar, N., & Fruttero, R. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100682 · Cited by 318 · cited 1×
“The synergistic effect of flavonoids can overcome the limitations on most anticancer medications caused by multidrug resistance [84].”
BackgroundNakanishi, T., & Ross, D. D. (2012) · Chinese Journal of Cancer · doi:10.5732/cjc.011.10320 · Cited by 301
Nanayakkara, A. K., Follit, C. A., Chen, G., Williams, N. S., Vogel, P. D., & Wise, J. G. (2018) · Scientific Reports · doi:10.1038/s41598-018-19325-x · Cited by 282 · cited 1×
“MRP is not usually comparable to the drug transporting P-gp in its actions [51].”
BackgroundLiposomal Nanomedicine: Applications for Drug Delivery in Cancer Therapy
Rommasi, F., & Esfandiari, N. (2021) · Nanoscale Research Letters · doi:10.1186/s11671-021-03553-8 · Cited by 269
Brangi, M., Litman, T., Ciotti, M., Nishiyama, K., Kohlhagen, G., Takimoto, C. H. M., Robey, R. W., Pommier, Y. G., Fojo, T., & Bates, S. E. (1999) · PubMed · Cited by 263
Liu, X. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-7647-4_2 · Cited by 254 · cited 1×
“P-gp is found on the biliary canalicular surfaces of hepatocytes, the luminal surfaces of jejunum and colon cells, the apical surfaces of the proximal tubular cells of the kidney, the endothelial cells of the blood–brain barrier, the apical membrane of the fetal membrane barrier function in the placenta, and other tis…”
BackgroundWang, J.-Q., Yang, Y., Cai, C.-Y., Teng, Q.-X., Cui, Q., Lin, J., Assaraf, Y. G., & Chen, Z.-S. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100743 · Cited by 241 · cited 1×
“Even if the resistant proteins are from the same ABC subfamily, they are quite different in terms of gene locus amin acid sequence, protein structure, and substrate [47].”
BackgroundA comprehensive framework for early-onset colorectal cancer research
Eng, C., Jácome, A. A., Agarwal, R., Hayat, M. H., Byndloss, M. X., Holowatyj, A. N., Bailey, C., & Lieu, C. H. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00588-x · Cited by 241
Gao, S., Yang, X., Xu, J., Qiu, N., & Zhai, G. (2021) · ACS Nano · doi:10.1021/acsnano.1c02103 · Cited by 236 · cited 2×
“However, in other types of tumor, there is decreased expression of P-gp during diagnosis, although it increases when the tissues are exposed to chemotherapeutic agents, which finally leads to the development of MDR in these cancerous cells [39].”
BackgroundABC Transporter-Mediated Multidrug-Resistant Cancer
Amawi, H., Sim, H.-M., Tiwari, A. K., Ambudkar, S. V., & Shukla, S. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-7647-4_12 · Cited by 228 · cited 1×
“The main cause of MDR is the overexpression of the ABC transporters [46].”
BackgroundMohammad, I. S., He, W., & Yin, L. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.038 · Cited by 218 · cited 1×
“Several agents that help to inhibit P-gp, such as calcium channel blockers, steroidal agents, protein kinase c inhibitors, immunosuppressive drugs, antibiotics, and surfactants, were found [40].”
BackgroundThreatening cancer with nanoparticle aided combination oncotherapy
Rawal, S., & Patel, M. M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.03.015 · Cited by 199 · cited 1×
“This lipophilic prodrug cleaves the lipids, leaving the parent drug behind, and is then delivered to tumor cells, causing cytotoxicity [91].”
BackgroundOvercoming multidrug resistance in cancer: Recent progress in nanotechnology and new horizons
Majidinia, M., Mirza‐Aghazadeh‐Attari, M., Rahimi, M., Mihanfar, A., Karimian, A., Safa, A., & Yousefi, B. (2020) · IUBMB Life · doi:10.1002/iub.2215 · Cited by 167 · cited 1×
“The increased expression of particular proteins, such as cell membrane transporters, which leads to a greater efflux of cytotoxic drugs from cancer cells, helps to lowering the intracellular concentration, leads to the development of drug resistance in cancer cells [34].”
BackgroundRather, R. A., & Bhagat, M. (2019) · Cancer Medicine · doi:10.1002/cam4.1411 · Cited by 167 · cited 1×
“These factors are dependent on the individual’s genetic patterns, which help to regulate the cellular responses, which, in turn, prevent the drug from reaching its threshold levels, which is usually required for pharmacological action to take place [42].”
BackgroundImpact of cancer metabolism on therapy resistance – Clinical implications
Gonçalves, A. C., Richiardone, E., Jorge, J., Polónia, B., Xavier, C. P. R., Salaroglio, I. C., Riganti, C., Vasconcelos, M. H., Corbet, C., & Sarmento-Ribeiro, A. B. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100797 · Cited by 164 · cited 4×
“This BRCP has a wide range of substrate specificities, which are usually different from but overlaps with P-gp or MRP-1 [53].”
BackgroundInfluentialRahman, M. M., Islam, M. R., Shohag, S., Hossain, M. E., Rahaman, M. S., Islam, F., Ahmed, M., Mitra, S., Khandaker, M. U., Idris, A. M., et al. (2022) · Molecules · doi:10.3390/molecules27051713 · Cited by 156 · cited 1×
“This formulation may overcome the barriers to treatment failure and may offer a new approach to producing cytotoxic outcomes in cancer cells [96].”
BackgroundSelf-citationEnteric coating of oral solid dosage forms as a tool to improve drug bioavailability
Maderuelo, C., Lanao, J. M., & Zarzuelo, A. (2019) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2019.105019 · Cited by 147 · cited 1×
“As a result, the drug’s bioavailability and therapeutic plasma concentration do not occur [79].”
BackgroundNatural Small Molecules in Breast Cancer Treatment: Understandings from a Therapeutic Viewpoint
Islam, M. R., Islam, F., Nafady, M. H., Akter, M., Mitra, S., Das, R. C., Urmee, H., Shohag, S., Akter, A., Chidambaram, K., et al. (2022) · Molecules · doi:10.3390/molecules27072165 · Cited by 146 · cited 1×
“This can make the therapeutic regimen much more difficult [15].”
BackgroundSelf-citationEliaa, S. G., Al-Karmalawy, A. A., Saleh, R. M., & Elshal, M. F. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00144 · Cited by 133 · cited 1×
“All of these effects are associated with drug resistance, but most studies carried out on this topic evaluate the changes associated with cellular pharmacology [21].”
BackgroundBiochemical Markers of Colorectal Cancer – Present and Future
Jelski, W., & Mroczko, B. (2020) · Cancer Management and Research · doi:10.2147/cmar.s253369 · Cited by 131 · cited 1×
“Colorectal cancer is any development, lump, or tumor that develops in the colorectal area [4].”
BackgroundThe ABC subfamily A transporters: Multifaceted players with incipient potentialities in cancer
Pasello, M., Giudice, A. M., & Scotlandi, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.004 · Cited by 129 · cited 1×
“The major reasons for studying resistance transporters and their activities are [29]:”
BackgroundThe role of photodynamic therapy on multidrug resistant breast cancer
Aniogo, E. C., George, B. P. A., & Abrahamse, H. (2019) · Cancer Cell International · doi:10.1186/s12935-019-0815-0 · Cited by 127 · cited 1×
“There are two leading hypothetical approaches to demonstrating the evolution of multidrug resistance, which usually results in treatment failure [11].”
BackgroundMilewska, S., Niemirowicz-Laskowska, K., Siemiaszko, G., Nowicki, P., Wilczewska, A. Z., & Car, H. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s323831 · Cited by 126 · cited 1×
“In addition to the aforementioned issues, the causes of therapy failure include rapid drug catabolism, poor absorption, and short biological half-life, all of which can be avoided by converting to lipid drug conjugates in lipid-based drug delivery systems [78].”
BackgroundFan, Y., Chen, M., Zhang, J., Maincent, P., Xia, X., & Wu, W. (2018) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2018024697 · Cited by 119 · cited 1×
“The major mechanism of resistance is related to the increased energy-dependent efflux of drugs from cells, which are then involved in the cloning of some of the transporters that are responsible for the efflux of the drugs in the first place [26].”
BackgroundHanssen, K. M., Haber, M., & Fletcher, J. I. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100795 · Cited by 102 · cited 1×
“Most of the transporters are overexpressed in human tumors, in addition to their physiological expression [37].”
BackgroundLipidic prodrug approach for improved oral drug delivery and therapy
Marković, M., Ben‐Shabat, S., Keinan, S., Aponick, A., Zimmermann, E. M., & Dahan, A. (2018) · Medicinal Research Reviews · doi:10.1002/med.21533 · Cited by 97 · cited 1×
“Subsequently, the TG is converted into lipoprotein and stored in the lymphatic system [89].”
BackgroundPectin based multi-particulate carriers for colon-specific delivery of therapeutic agents
Das, S. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120814 · Cited by 93 · cited 2×
“The third alteration, is the most important in the development of drug resistance changes in the differential pathway and homeostasis responses within tumors [19].”
BackgroundPhytochemicals reverse P-glycoprotein mediated multidrug resistance via signal transduction pathways
Muthusamy, G., Kanimozhi, G., Bharathiraja, P., Khan, H. A., Alhomida, A. S., Ekhzaimy, A. A., Brindha, G., & Prasad, N. R. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111632 · Cited by 93 · cited 2×
“When adriamycin and curcumin were combined, the Western blotting results showed that it could cleave PARP inhibitors and overcome P-gp-induced MDR. Curcumin has previously been shown, in animal studies and cell culture assays, to have anti-cancer properties [86].”
BackgroundWang, Z., Zhan, Y., Xu, J., Wang, Y., Sun, M., Chen, J., Liang, T., Wu, L., & Xu, K. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.0c00107 · Cited by 80 · cited 1×
“The pharmacological inhibition of proteasomes leads to the increased accumulation of the P53 protein, which finally leads to apoptosis in cancer cells [64].”
BackgroundGoebel, J., Chmielewski, J., & Hrycyna, C. (2021) · Cancer Drug Resistance · doi:10.20517/cdr.2021.19 · Cited by 79 · cited 1×
“The location of MRP at the subcellular level was not the same as that of the plasma membrane transporter-like P-gp [49].”
BackgroundAmodio, V., Mauri, G., Reilly, N. M., Bianchi, A. S., Siena, S., Bardelli, A., & Germano, G. (2021) · Cancers · doi:10.3390/cancers13112638 · Cited by 74 · cited 1×
“It inhibits the promotion and progression of carcinogenesis while also influencing the formation of colon cancer cells with DNA mismatch repair defects [87].”
BackgroundWhere is it and How Does it Get There – Intracellular Localization and Traffic of P-glycoprotein
Fu, D. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00321 · Cited by 74 · cited 1×
“The 26 s proteasome is a supra-molecular protein assembly that exhibits a major role in degrading the proteins that are involved in the regulation of the cell cycle [61].”
BackgroundTargeting KRAS: The Elephant in the Room of Epithelial Cancers
Merz, V., Gaule, M., Zecchetto, C., Cavaliere, A., Casalino, S., Pesoni, C., Contarelli, S., Sabbadini, F., Bertolini, M., Mangiameli, D., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.638360 · Cited by 70 · cited 1×
“are often found to have mutations in their targets or to bypass the mutations al together [17].”
BackgroundABCB1/MDR1/P‐gp employs an ATP‐dependent twist‐and‐squeeze mechanism to export hydrophobic drugs
Kodan, A., Futamata, R., Kimura, Y., Kioka, N., Nakatsu, T., Kato, H., & Ueda, K. (2020) · FEBS Letters · doi:10.1002/1873-3468.14018 · Cited by 67 · cited 1×
“The substrate is transported to P-gp via a cytoplasmic opening or an entrance in the membrane’s inner leaflet [80].”
BackgroundOral drugs in the treatment of metastatic colorectal cancer
Alfonso, P. G., Martín, A. J. M., Morán, L. O., Alsar, J. S., Pérez-Solero, G. T., Codesido, M. B., Ferrandiz, P. A. C., & Cicala, S. G. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211009001 · Cited by 64
Eid, S. Y., Althubiti, M., Abdallah, M. E., Wink, M., & El-Readi, M. Z. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153280 · Cited by 64 · cited 1×
“MDR occurs when in vitro tumor cells are exposed to a cytotoxic agent that has developed cross-resistance to all the compounds that are unrelated structurally and functionally [33].”
BackgroundAbdallah, E. A., Fanelli, M. F., Souza, E. S. V., Netto, M. C. M., Gasparini, J. L., Araújo, D. V., Ocea, L. M. M., Buim, M. E. C., Tariki, M. S., Alves, V. S., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30082 · Cited by 63 · cited 1×
“If these findings are verified, they will have significant implications for the function of BCRP in clinical oncology [60].”
BackgroundCurcumin: A therapeutic strategy for colorectal cancer?
de Porras, V. R., Layos, L., & Martinez‐Balibrea, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.09.004 · Cited by 61
Developmental origins and oncogenic pathways in malignant brain tumors
Lu, Q. R., Qian, L., & Zhou, X. (2019) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.342 · Cited by 60 · cited 1×
“Furthermore, it was discovered that these belong to the family of ATP-dependent transporters, called ABC transporters, of which four are known in humans [27].”
BackgroundDrug-adapted cancer cell lines as preclinical models of acquired resistance
Michaelis, M., Wass, M. N., & Cinatl, J. J. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.005 · Cited by 60 · cited 1×
“Cancer cell populations can be intrinsically resistant, meaning they do not respond to anti-cancer drugs at all; or, even if they are essentially sensitive to treatment, they can be resistant to some drugs over the course of therapy thereby acquiring resistance [10].”
BackgroundSindhu, R. K., Najda, A., Kaur, P., Shah, M., Singh, H., Kaur, P., Cavalu, S. D., Jaroszuk-Sierocińska, M., & Rahman, M. H. (2021) · Materials · doi:10.3390/ma14205965 · Cited by 57 · cited 2×
“Flavonoids are the most common polyphenolic compound in the human diet, along with the secondary metabolites originating in both plants and animals [14].”
BackgroundSelf-citationMiere, F. G., Vicaş, S. I., Timar, A., Ganea, M., Zdrîncă, M. M., Cavalu, S. D., Fritea, L., Vicaș, L. G., Muresan, M. E., Pallag, A., et al. (2021) · Processes · doi:10.3390/pr9030432 · Cited by 55
Self-citationElfadadny, A., El‐Husseiny, H. M., Abugomaa, A., Ragab, R. F., Mady, E. A., Aboubakr, M., Samir, H., Mandour, A. S., El‐Mleeh, A., El‐Far, A. H., et al. (2021) · Environmental Science and Pollution Research · doi:10.1007/s11356-021-15759-5 · Cited by 52 · cited 1×
“P-gp is expressed in the epithelial cells present in the colon, kidney, adrenal pancreas, and liver, which leads to resistance to a few cytotoxic agents before the commencement of chemotherapy in the case of cancerous tissues [38].”
BackgroundPaškevičiūtė, M., & Petrikaitė, V. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0584-7 · Cited by 48 · cited 1×
“Another reason for chemotherapy failure is the multidrug resistance produced by cancer cells to a wide range of anticancer drugs [68].”
BackgroundAbdelfatah, S., Böckers, M., Asensio, M., Kadioglu, O., Klinger, A., Fleischer, E., & Efferth, T. (2020) · Phytomedicine · doi:10.1016/j.phymed.2020.153196 · Cited by 48 · cited 1×
“The overexpression of P-gp is found in MDR, which results in a greater efflux of chemotherapy in cancer cells [31].”
BackgroundWaku, T., Nakamura, N., Koji, M., Watanabe, H., Katoh, H., Tatsumi, C., Tamura, N., Hatanaka, A., Hirose, S., Katayama, H., et al. (2020) · Molecular and Cellular Biology · doi:10.1128/mcb.00597-19 · Cited by 47 · cited 1×
“As the levels of the P53 suppressor are consistently low due to the ubiquitin proteasomal system, proteasomal inhibitors are required [63].”
BackgroundRajput, A., Pingale, P., Telange, D. R., Chalikwar, S. S., & Borse, V. B. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102934 · Cited by 46 · cited 1×
“The lymphatic system’s function in transporting dietary lipids from the intestine to the lymphatic capillaries allows the lipid drug mixture to efficiently use this pathway, integrate into the enterocytes, and arrive in the lymphatic capillaries, thereby overcoming the first-pass metabolism observed during oral drug a…”
BackgroundCurcumin as a great contributor for the treatment and mitigation of colorectal cancer
Karthika, C., Hari, B., Mano, V., Radhakrishnan, A., Janani, S. K., Akter, R., Kaushik, D. K., & Rahman, M. H. (2021) · Experimental Gerontology · doi:10.1016/j.exger.2021.111438 · Cited by 45 · cited 2×
“Curcumin, a naturally occurring flavonoid, has been shown in numerous studies to have anti-cancer and MDR inhibition properties [71].”
BackgroundSelf-citationThymoquinone-chemotherapeutic combinations: new regimen to combat cancer and cancer stem cells
El‐Far, A. H., Tantawy, M. A., Jaouni, S. K. A., & Mousa, S. A. (2020) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-020-01898-y · Cited by 41 · cited 1×
“As the tumor cells begin to multiply, chemotherapy fails, since the new tumor cells are now resistant to the therapeutic regimen [32].”
BackgroundCurcumin ameliorated ventilator-induced lung injury in rats
Wang, X., An, X., Wang, X., Bao, C., Li, J., Yang, D., & Bai, C. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.12.100 · Cited by 41 · cited 1×
“Drug-sensitive cells are killed by chemotherapy, but the major drawback of this approach is that cells that are resistant to the drug are left behind [30].”
BackgroundCavalu, S. D., Bisboaca, S., Mateș, I. M., Pasca, P. M., Laslo, V., Costea, T. O., Fritea, L., & Vicaş, S. I. (2019) · Revista de Chimie · doi:10.37358/rc.18.12.6836 · Cited by 41
Self-citationLindner, S., Halwachs, S., Wassermann, L., & Honscha, W. (2013) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12045 · Cited by 39
Ishida, T., Takahashi, T., Kurokawa, Y., Nishida, T., Hirota, S., Serada, S., Fujimoto, M., Naka, T., Teranishi, R., Saito, T., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01566-9 · Cited by 38 · cited 1×
“This has been demonstrated using sophisticated molecular techniques [12].”
MethodResearch Progress in Flavonoids as Potential Anticancer Drug Including Synergy with Other Approaches
Hussain, Y., Luqman, S., & Meena, A. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200502005411 · Cited by 38 · cited 1×
“Many mechanisms lead to the development of MDR, such as increases in the drug efflux from the cells by ATP-dependent transporters, decreases in drug uptake by cells, the activation of detoxifying enzymes, and defective apoptotic pathways [35].”
BackgroundRazzaq, S., Rauf, A., Raza, A., Akhtar, S., Tabish, T. A., Sandhu, M. A., Zaman, M., Ibrahim, I. M., Shahnaz, G., Rahdar, A., et al. (2021) · Nanomaterials · doi:10.3390/nano11112858 · Cited by 38 · cited 1×
“Anticancer drugs are administered along with the inhibitors so that the transporter proteins are kept occupied and the drug is allowed to accumulate in the cancer cells at an effective lethal concentration, as the inhibitors, when considered on a chemical basis, cause intrinsic toxicity or produce undesired effects [4…”
BackgroundThe Cytotoxicity and Clearance of Mutant Huntingtin and Other Misfolded Proteins
Folger, A., & Wang, Y. (2021) · Cells · doi:10.3390/cells10112835 · Cited by 32 · cited 2×
“This proteasomes is responsible for providing cells with a recycler function in damaged or misfolded proteins [57].”
BackgroundMicroscopic and spectroscopic investigation of bioactive glasses for antibiotic controlled release
Cavalu, S. D., Bănică, F., Gruian, C., Vanea, E., Göller, G., & Simon, V. (2013) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2013.02.016 · Cited by 31 · cited 1×
“This ultimately results in deviations in the local environments of tumor cells, including the development of other cell types, which are not cancerous but can affect responses to chemotherapy, as well as alterations in the substrates where the cells sit [20].”
BackgroundSelf-citationKisiel, J. B., Papadopoulos, N., Liu, M., Crosby, D. L., Srivastava, S., & Hawk, E. T. (2022) · Cancer · doi:10.1002/cncr.33912 · Cited by 30 · cited 1×
“If the drugs can enter the cells, some mechanisms affect the cell biology, which has profound effects on drug resistance, such as reduced cell death by pathways, known as apoptosis, altered cell-cycle checkpoints or growth pathways, the altered metabolism of drugs within cells, altered targets, or increased damage rep…”
BackgroundChemo-Preventive Action of Resveratrol: Suppression of p53—A Molecular Targeting Approach
Akter, R., Rahman, M. H., Kaushik, D. K., Mittal, V., Uivaroșan, D., Nechifor, A. C., Behl, T., Karthika, C., Stoicescu, M., Munteanu, M. A., et al. (2021) · Molecules · doi:10.3390/molecules26175325 · Cited by 29 · cited 1×
“The p53 tumor-suppressor protein is one of the important biological targets of proteasomes [62].”
BackgroundSelf-citationFigueira-Mansur, J., Schrago, C. G., Salles, T. S., Alvarenga, E. S. L., Vasconcellos, B. M., Melo, A. C. A., & Moreira, M. F. (2020) · BMC Genomics · doi:10.1186/s12864-020-06873-8 · Cited by 28 · cited 1×
“P-gp is part of the ATPbinding cassette (ABC) family of transporters, which currently has 48 members that have sequential and structural homology [36].”
BackgroundSteps to address anti-microbial drug resistance in today’s drug discovery
Parish, T. (2018) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1550481 · Cited by 28 · cited 1×
“In most cases, this is the major reason for the development of resistance [16].”
BackgroundWang, Y., Imai, Y., Shiseki, M., Tanaka, J., & Motoji, T. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.01.020 · Cited by 24
Metabolism and pharmacokinetic optimization strategies in drug discovery
Ballard, P. G., Brassil, P. J., Bui, K., Dolgos, H., Petersson, C., Tunek, A., & Webborn, P. J. H. (2013) · Elsevier eBooks · doi:10.1016/b978-0-7020-4299-7.00010-x · Cited by 22
Karthika, C., & Sureshkumar, R. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109325 · Cited by 21 · cited 1×
“The multi-use of lipids provides several advantages, including improved bioavailability, drug targeting to tumor cells, the lymphatic targeting of the drug, which has benefits during the metastatic stage, and abridged toxicity [70].”
BackgroundSelf-citationKarthika, C., Sureshkumar, R., Sajini, D. V., Ashraf, G. M., & Rahman, M. H. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-20208-y · Cited by 20
Self-citationPotential Use of Nanomedicine for the Anti-inflammatory Treatment of Neurodegenerative Diseases
Otero, M. D. C., Espinosa‐Oliva, A. M., Herrera, A. J., García-Domínguez, I., Arévalo, M. F., Martín‐Banderas, L., & de Pablos, R. M. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612824666180403113015 · Cited by 20 · cited 1×
“These findings support our hypothesis that flavonoids can be used to enhance the activity of first-line therapy as an antiproliferative agent [72].”
BackgroundNatural Product-Based Chemical Herbicides
Duke, S. O., Owens, D. K., & Dayan, F. E. (2018) · CRC Press eBooks · doi:10.1201/9781315155913-8 · Cited by 17 · cited 1×
“Natural inhibitors have a greater potential impact on safety, efficacy, and cost than chemical or synthetic inhibitors [83].”
BackgroundIs viral E6 oncoprotein a viable target? A critical analysis in the context of cervical cancer
Kumar, A., Rathi, E., Hariharapura, R. C., & Kini, S. G. (2020) · Medicinal Research Reviews · doi:10.1002/med.21697 · Cited by 14 · cited 1×
“In the fight against cancer, a large number of targets are pursued with the same zeal [54].”
BackgroundIncorporation of natural assumption to deal with cancer
Karthika, C., & Sureshkumar, R. (2020) · Environmental Science and Pollution Research · doi:10.1007/s11356-020-11479-4 · Cited by 11 · cited 1×
“As the natural compounds used are essential in the human diet, it can be stated that there would be very few side effects [45].”
BackgroundSelf-citationSimon, S., Cavalu, S. D., Eniu, D., & Simon, V. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.130341 · Cited by 10 · cited 1×
“Below, we present the resistance components of cancer in general and colorectal cancer in particular and postulate a concept that includes combination therapy with 5-fluorouracil, curcumin, and lipids for the potential management of colorectal cancer [9].”
BackgroundSelf-citationAsano, H., Fukano, H., Takagi, M., & Takayama, T. (2022) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2022.03.026 · Cited by 10 · cited 1×
“Metastasis, or the spread of cancer cells to further parts of the body, is most common in the fourth stage, or the Duke E stage, and is caused by cancer cells spreading through the lymph nodes, which is also the main reason for the disease’s reappearance after treatment [7].”
BackgroundPresenting an expert system for early diagnosis of gastrointestinal diseases
Mirmozaffari, M. (2019) · International Journal of Gastroenterology Sciences · doi:10.33545/26649209.2019.v1.i1a.4 · Cited by 9 · cited 1×
“It can cause rectal irritation, painful bowel movements, and blood in the stool in some patients [67].”
BackgroundRole of Plant Secondary Metabolites as Modulators of Multidrug Resistance in Cancer Therapy
Chaudhary, M. (2022) · Springer eBooks · doi:10.1007/978-981-16-4779-6_13 · Cited by 6
Karthika, C., Sureshkumar, R., Sajini, D. V., Ash, G. M., & Rahman, M. H. (2021) · Research Square · doi:10.21203/rs.3.rs-1070585/v1 · Cited by 5
Self-citationOvercoming cancer resistance to chemotherapy through HPMA copolymer conjugates
Sivák, L. (2019) · Digital Repository (National Repository of Grey Literature) · Cited by 2
Research works printed but not linked: 4
- Sosnik, A., and Bendayan, R. (2019). Drug Efflux Pumps in Cancer Resistance Pathways: From Molecular Recognition and Characterization to Possible Inhibition Strategies in Chemotherapy, Academic Press.
- Power, J.F. (2018). The Role of Extracellular Vesicles in the Transfer of Multidrug Resistance in Human Ovarian Cancer Cells. [Master’s Thesis, Queen’s University].
- Ahmed, A.H. (2021). Identifying Anti-Cancer Drugs Targeting ALK Inhibitors with P-Glycoprotein and Studying It’s Molecular Mechanism of Transport. [Ph.D. Thesis, University of Georgia].
- Zargan, 2022, Evaluation of the Anti-Cancer Effect of Curcumin on MCF-7 Cells in 3D Culture Conditions to Increase the Efficacy of Breast Cancer Treatment, J. Appl. Biotechnol. Rep., 9, 547
Cited by
Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success
Ashique, S., Bhowmick, M., Pal, R., Khatoon, H., Kumar, P., Sharma, H., Garg, A., Kumar, S., & Das, U. (2024) · Advances in Cancer Biology - Metastasis · doi:10.1016/j.adcanc.2024.100114 · Cited by 139
Multidrug Resistance of Cancer Cells and the Vital Role of P-Glycoprotein
Karthika, C., Sureshkumar, R., Zehravi, M., Akter, R., Ali, F., Ramproshad, S., Mondal, B., Tagde, P., Ahmed, Z., Khan, F. S., et al. (2022) · Life · doi:10.3390/life12060897 · Cited by 181
“Modifying P-gp function using various inducers, inhibitors, or genetic polymorphisms is a common strategy [110].”
BackgroundSelf-citationMechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Furthermore, defective apoptotic pathways can contribute to MDR [45].”
New insights into targeted therapy of glioblastoma using smart nanoparticles
Ghaznavi, H., Afzalipour, R., Khoei, S., Sargazi, S., Shirvalilou, S., & Sheervalilou, R. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03331-3 · Cited by 56
“Another major barrier against the efficacy of anticancer treatment is MDR [95].”
BackgroundPhytocompounds and Nanoformulations for Anticancer Therapy: A Review
Bozzuto, G., Calcabrini, A., Colone, M., Condello, M., Dupuis, M. L., Pellegrini, E., & Stringaro, A. (2024) · Molecules · doi:10.3390/molecules29163784 · Cited by 46
“However, the effectiveness of therapy is very often limited by the onset of drug resistance due to epigenetic factors, changes in drug metabolism, increases in drug efflux mediated by ATP-binding cassette transporters, increased DNA repair, and autophagy induction [89].”
Background
Metadata
- Authors
- Karthika, C., Sureshkumar, R., Zehravi, M., Akter, R., Ali, F., Ramproshad, S., Mondal, B., Kundu, M. K., Dey, A., Rahman, M. H., Antonescu, A., & Cavalu, S.
- Affiliations
- JSS Academy of Higher Education and Research (IN)
- Prince Sattam Bin Abdulaziz University (SA)
- Yonsei University (KR)
- Department of Licensing and Enforcement, Laboratory Services, Botswana Medicines Regulatory Authority (BoMRA), Gaborone 999106, Botswana
- R. P. Shaha University (BD)
- Khulna University (BD)
- Presidency University (IN)
- University of Oradea (RO)
- Corresponding author
- Sureshkumar, Raman
- Rahman, Md. Habibur
- Cavalu, Simona
- ORCID
- Venue
- Life
- Publisher
- MDPI AG
- Published
- 2022-05-30
- Volume
- 12
- Issue
- 6
- Pages
- 811
- ISSN
- 2075-1729 (ISSN-L)
- PMC
- PMC9224881
- OpenAlex
- W4281679094
- Cited by
- 30
- References
- 94
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 10 · 2023: 6 · 2022: 4
- FWCI
- 0.82
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Life (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Department of Science and Technology, Ministry of Science and Technology, India
- Indian Council of Medical Research
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- multidrug resistance, colorectal cancer, combination therapy, 5-fluorouracil, curcumin, lipids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.